Jim Finnel
Fallen Cannabis Warrior & Ex News Moderator
Hexahydrocannabinols, novel synthetic cannabinoid derivatives, suppress the tumor growth by inhibiting the VEGF secretion and angiogenesis
Dinesh Thapa1, Jong Suk Lee1, Likai Xia2, Yong Rok Lee2 and Jung-Ae Kim1
1 College of Pharmacy
2 School of Chemical Engineering and Technology, Yeungnam University, Gyeongsan, Korea, Republic of
ABSTRACT
Cannabinoids, the active components of Cannabis sativa L. have been shown to exert antiproliferative actions in wide spectrum of tumor cells. However, the specific mechanism and target for these processes remain poorly understood. In the present study we examined anticancer potentials of hexahydrocannabinols. The synthetic hexahydrocannabinols inhibited the vascular endothelial growth factor (VEGF)-induced angiogenesis on in vivo chick chorioalantoic membrane (CAM) assay. In addition, hexahydrocannabinols suppressed VEGF-stimulated proliferation, tube formation, and migration in a concentration-dependent manner. In MCF-7 cells, hexahydrocannabinols concentration-dependently inhibited VEGF secretion. Furthermore, we found that the hexahydrocannabinols dose-dependently inhibited tumor growth and tumor-induced angiogenesis. In addition, these synthetic cannabinoids significantly inhibited the TPA-induced NF-B activation, which is known to regulate many important genes for inflammation, angiogenesis, and tumor growth. Overall, these findings strongly suggest that synthetic hexahydrocannabinols may be the promising compounds for antitumor drug development.
Source: Hexahydrocannabinols, novel synthetic cannabinoid derivatives, suppress the tumor growth by inhibiting the VEGF secretion and angiogenesis -- Thapa et al. 23 (1): 761.3 -- The FASEB Journal
Dinesh Thapa1, Jong Suk Lee1, Likai Xia2, Yong Rok Lee2 and Jung-Ae Kim1
1 College of Pharmacy
2 School of Chemical Engineering and Technology, Yeungnam University, Gyeongsan, Korea, Republic of
ABSTRACT
Cannabinoids, the active components of Cannabis sativa L. have been shown to exert antiproliferative actions in wide spectrum of tumor cells. However, the specific mechanism and target for these processes remain poorly understood. In the present study we examined anticancer potentials of hexahydrocannabinols. The synthetic hexahydrocannabinols inhibited the vascular endothelial growth factor (VEGF)-induced angiogenesis on in vivo chick chorioalantoic membrane (CAM) assay. In addition, hexahydrocannabinols suppressed VEGF-stimulated proliferation, tube formation, and migration in a concentration-dependent manner. In MCF-7 cells, hexahydrocannabinols concentration-dependently inhibited VEGF secretion. Furthermore, we found that the hexahydrocannabinols dose-dependently inhibited tumor growth and tumor-induced angiogenesis. In addition, these synthetic cannabinoids significantly inhibited the TPA-induced NF-B activation, which is known to regulate many important genes for inflammation, angiogenesis, and tumor growth. Overall, these findings strongly suggest that synthetic hexahydrocannabinols may be the promising compounds for antitumor drug development.
Source: Hexahydrocannabinols, novel synthetic cannabinoid derivatives, suppress the tumor growth by inhibiting the VEGF secretion and angiogenesis -- Thapa et al. 23 (1): 761.3 -- The FASEB Journal
